Our Products
Loans
Cards
Insurance
Investment
Stock Market
Electronics Mall
CIBIL Score
Knowledge Centre
Academy 
Calculators
Our Services
My Account
Do not call
En
Astrazeneca Pharma India Ltd. Share Price
Day's Range
Day's Range
Low
₹8,554.00
High
₹8,679.00
Price Summary
| Previous Close | ₹8,655.50 |
|---|---|
| Day's Range | ₹8,554.00 - ₹8,679.00 |
| Open | ₹8,609.00 |
| 52 Week Range | ₹7,551.50 - ₹10,691.00 |
| Volume | 638 |
| Market Cap | ₹0.02 |
Stocks Summary
| Trade Value ( ₹ in Lacs) | 55.22 |
|---|---|
| Market Cap (₹ in Mn) | 0.02 |
| Dividend Yield(%) | 0.37 |
| Price/Earning (TTM) | 107.08 |
| TTM EPS (₹) | 80.36 |
| P/E Ratio | 185.90 |
| Book Value(₹) | 25.87 |
| PAT Margin (%) | 6.72 |
| Face Value (₹) | 2.00 |
| ROCE(%) | 21.29 |
Financials
| Particulars | QTR FY (₹ in Millions) | Annual FY (₹ in Millions) |
|---|---|---|
| Net sales | 4402.9 | 12955.3 |
| Expenses | N/A | N/A |
| PBT | 420.2 | 2195.4 |
| Operating profit | 0.0 | 0.0 |
| Net profit | 308.5 | 1615.1 |
About Astrazeneca Pharma India Ltd.
| Founded | 1979 |
|---|---|
| NSE Symbol | ASTRAZEN |
Peer Comparision
| Stocks Name | Market Cap (Cr)(₹) | Market Price (₹) | 52 Week Low-High (₹) |
|---|---|---|---|
| Sun Pharmaceutical Industries Ltd. | 4,42,725.29 | 1,840.00 | 1,548.00 - 1,548.00 |
| Divi's Laboratories Ltd. | 1,82,775.12 | 6,920.00 | 5,636.50 - 5,636.50 |
| Torrent Pharmaceuticals Ltd. | 1,51,764.01 | 4,570.00 | 3,102.00 - 3,102.00 |
| Apollo Hospitals Enterprise Ltd. | 1,20,200.38 | 8,500.00 | 6,696.50 - 6,696.50 |
| Cipla Ltd. | 1,13,007.26 | 1,399.00 | 1,165.70 - 1,165.70 |
| Dr. Reddy's Laboratories Ltd. | 1,09,098.01 | 1,319.10 | 1,148.40 - 1,148.40 |
| Zydus Lifesciences Ltd. | 1,04,542.68 | 1,050.00 | 835.50 - 835.50 |
| Lupin Ltd. | 1,04,222.36 | 2,302.25 | 1,836.80 - 1,836.80 |
| Mankind Pharma Ltd. | 1,02,422.13 | 2,479.00 | 1,909.70 - 1,909.70 |
| Max Healthcare Institute Ltd. | 99,587.17 | 1,025.00 | 903.00 - 903.00 |
No Records Found
Latest News
AstraZeneca Pharma India informs about appointment of senior management personnel
Pursuant to Regulation 30 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015 (‘SEBI Listing Regulations’), AstraZeneca Pharma India has informed that based on the recommendation of the Nomination and Remuneration Committee, the Board of Directors of the Company has approved the appointment of Sandhya Tejaswini Amanna as Director - Legal, with effect from March 18, 2026. This being a Senior Management Personnel position in terms of the SEBI Listing Regulations, it has enclosed details as required under the SEBI Circular No. HO/49/14/14(7)2025 - CFD-POD2/I/3762/2026 dated January 30, 2026, attached as Annexure -A.
The above information is a part of company’s filings submitted to BSE.
AstraZeneca Pharma India informs about notice of postal ballot
AstraZeneca Pharma India has informed that it enclosed the Postal Ballot Notice dated February 11, 2026, being sent to the members of the Company to their registered email addresses, seeking their approval for the special business as set out therein. The Notice is being sent to the members whose names appear in the Register of Members/ Record of Depositories as on the cut-off date being Friday, February 20, 2026. The e-voting period commences on Saturday, February 28, 2026 (9:00 am IST) and ends on Sunday, March 29, 2026 (05:00 pm IST). The Company has engaged the services of National Securities Depository for facilitating e-voting in a secure manner. The said information is also available on the website of the Company: www.astrazeneca.com/india.
The above information is a part of company’s filings submitted to BSE.
Oxygenta Pharma - Quaterly Results
| (Rs. in Million) |
| Quarter ended | Year to Date | Year ended | |||||||
| 202603 | 202503 | % Var | 202603 | 202503 | % Var | 202603 | 202503 | % Var | |
| Sales | 496.14 | 494.67 | 0.30 | 1129.82 | 1092.99 | 3.37 | 1129.82 | 1092.99 | 3.37 |
| Other Income | 1.73 | 0.49 | 253.06 | 2.86 | 13.09 | -78.15 | 2.86 | 13.09 | -78.15 |
| PBIDT | 2.87 | -19.05 | -115.07 | -150.80 | -87.76 | 71.83 | -150.80 | -87.76 | 71.83 |
| Interest | 18.08 | 21.28 | -15.04 | 47.77 | 19.61 | 143.60 | 47.77 | 19.61 | 143.60 |
| PBDT | -15.21 | -40.33 | -62.29 | -198.57 | -107.37 | 84.94 | -198.57 | -107.37 | 84.94 |
| Depreciation | -2.41 | -2.34 | 2.99 | 23.23 | 36.14 | -35.72 | 23.23 | 36.14 | -35.72 |
| PBT | -12.80 | -37.99 | -66.31 | -221.80 | -143.51 | 54.55 | -221.80 | -143.51 | 54.55 |
| TAX | 4.24 | -16.48 | -125.73 | -46.09 | -40.53 | 13.72 | -46.09 | -40.53 | 13.72 |
| Deferred Tax | 4.24 | -18.08 | -123.45 | -46.09 | -42.13 | 9.40 | -46.09 | -42.13 | 9.40 |
| PAT | -17.04 | -21.51 | -20.78 | -175.71 | -102.98 | 70.63 | -175.71 | -102.98 | 70.63 |
| Equity | 369.84 | 369.84 | 0.00 | 369.84 | 369.84 | 0.00 | 369.84 | 369.84 | 0.00 |
| PBIDTM(%) | 0.58 | -3.85 | -115.02 | -13.35 | -8.03 | 66.23 | -13.35 | -8.03 | 66.23 |
Divi's Lab - Quaterly Results
| (Rs. in Million) |
| Quarter ended | Year to Date | Year ended | |||||||
| 202603 | 202503 | % Var | 202603 | 202503 | % Var | 202603 | 202503 | % Var | |
| Sales | 27930.00 | 25360.00 | 10.13 | 103880.00 | 91980.00 | 12.94 | 103880.00 | 91980.00 | 12.94 |
| Other Income | 1540.00 | 870.00 | 77.01 | 5060.00 | 3520.00 | 43.75 | 5060.00 | 3520.00 | 43.75 |
| PBIDT | 10970.00 | 9680.00 | 13.33 | 39940.00 | 33310.00 | 19.90 | 39940.00 | 33310.00 | 19.90 |
| Interest | 60.00 | 0.00 | 0.00 | 230.00 | 10.00 | 2200.00 | 230.00 | 10.00 | 2200.00 |
| PBDT | 10910.00 | 9680.00 | 12.71 | 38970.00 | 33300.00 | 17.03 | 38970.00 | 33300.00 | 17.03 |
| Depreciation | 1200.00 | 1070.00 | 12.15 | 4610.00 | 4010.00 | 14.96 | 4610.00 | 4010.00 | 14.96 |
| PBT | 9710.00 | 8610.00 | 12.78 | 34360.00 | 29290.00 | 17.31 | 34360.00 | 29290.00 | 17.31 |
| TAX | 2150.00 | 1940.00 | 10.82 | 8290.00 | 7200.00 | 15.14 | 8290.00 | 7200.00 | 15.14 |
| Deferred Tax | -350.00 | -310.00 | 12.90 | -400.00 | -730.00 | -45.21 | -400.00 | -730.00 | -45.21 |
| PAT | 7560.00 | 6670.00 | 13.34 | 26070.00 | 22090.00 | 18.02 | 26070.00 | 22090.00 | 18.02 |
| Equity | 530.00 | 530.00 | 0.00 | 530.00 | 530.00 | 0.00 | 530.00 | 530.00 | 0.00 |
| PBIDTM(%) | 39.28 | 38.17 | 2.90 | 38.45 | 36.21 | 6.17 | 38.45 | 36.21 | 6.17 |
Concord Biotech informs about board meeting
Concord Biotech has informed that the meeting of the Board of Directors of the Company is scheduled on 29/05/2026, inter alia, to consider and approve the audited Standalone and Consolidated Financial Results for the fourth quarter and financial year ended March 31, 2026 along with audit report thereon and subject to approval of shareholders at the ensuing Annual General Meeting, to recommend final dividend on equity shares of the Company.
The above information is a part of company’s filings submitted to BSE.
No Records Found
Sign in to Unlock Offers!
We don't SPAM
Frequently Asked Questions
The current share price of Astrazeneca Pharma India Ltd. is ₹8,655.50 as of 2026-05-25.
The market capitalisation of Astrazeneca Pharma India Ltd. is ₹21,510.62 as of 2026-05-22.
The 1-year return of Astrazeneca Pharma India Ltd. is 68.00% as of 2026-05-25.
The P/E ratio of Astrazeneca Pharma India Ltd. is 185.90 as of 2026-05-25.
The 52-week high and low of Astrazeneca Pharma India Ltd. are ₹10,691.00 and ₹7,551.50, respectively, as of 2026-05-25.
Disclaimer
All content and research information displayed on the Site, are obtained from our partner Accord Fintech Private Limited. an authorized data feed vendor of BSE/NSE/MCX/NCDEX exchange. The data is provided on ‘As-Is’ basis and is not a live data feed but a feed with 15 minutes delay or more. Bajaj Markets does not warrant accuracy, completeness, timely availability of the information and data available on the Site. Past performance, when presented, is purely for reference purposes and is not a guarantee of similar future results.
The Services offered on the Site does not constitute investment advice in any manner whatsoever. You shall be solely responsible for any investment decisions made by placing reliance on the information provided on the Site.
Bajaj Markets partners with financial services entities for sourcing leads for services such as DEMAT accounts etc. In case you wish to avail the services, you shall be redirected to partners platform and shall be bound by the terms and conditions, privacy policy governing the said platform.
